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JURISDICTIONAL STATEMENT 
This appeal is filed pursuant to Utah Code Ann. , 
§78-2-2(3)(i) (1987). The interlocutory order appealed from 
contains an express direction pursuant to Rule 54(b) that no 
just reason exists to delay the appeal, and directing entry 
of the order as a final judgment. 
NATURE OF THE PROCEEDINGS 
Celia Anderson underwent an experimental series of 
injections of liquid silicone into her face. She suffered a 
grotesque and disfiguring result. Defendant WooIf was the 
doctor who actually performed the experimental injections; 
defendant Dow supplied the silicone. Defendant Goldwyn was 
a medical doctor appointed to monitor the experiment? 
defendant American Society of Plastic and Reconstructive 
Surgeons, Inc. (ASPRS) jointly administered the experimental 
program with defendant Dow. 
This is an appeal from an order of the Third 
Judicial District Court dismissing plaintiff's complaint 
against defendants Goldwyn and the ASPRS for lack of in 
personam jurisdiction. 
1 
STATEMENT OF ISSUES PRESENTED ON APPEAL 
1. Whether the trial court erred in concluding, 
as a matter of law, that defendants Goldwyn and the ASPRS 
did not cause injury to Celia in Utah? 
2. Was the trial court's conclusion that juris-
diction over Goldwyn and the ASPRS would violate federal due 
process correct? 
STATEMENT OF FACTS 
1.. Background. 
Dow Corning tested liquid silicone for over ten 
years from 1965 to 1975. In 1975, the FDA approved liquid 
silicone for the most severe cases of facial deformity. Dow 
elected not to market silicone under those restrictions. 
The plastic surgeon community (principal users of silicone) 
was upset at the lack of availability of silicone. The 
ASPRS, on behalf of the plastic surgeon community, ap-
proached Dow to devise a formula to make liquid silicone 
available. See generally Goldwyn deposition, R.1810, 
Deposition Exhibit 13, Letter of Rathjen, 10/28/83. 
2. Agreement to co-sponsor liquid silicone study. 
The formula worked out by Dow and the ASPRS 
involved joint sponsorship of a new "study" of liquid 
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silicone. This agreement was worked out in a series of 
meetings in 1976 and 1977. The final meeting was in March 
24, 1977 in Los Angeles. Proposed Minutes of the meeting 
drafted by ASPRS and Dow show that this was a formal, 
arms-length negotiation and agreement. (See ASPRS minutes 
of 4/18/77, R.1669, attached hereto as Exhibit A; Dow 
Corning minutes of 4/11/77, R.1670, Exhibit B; Dow Corning 
reply minutes of 5/18/77, Exhibit C.) 
Construing the minutes together, the essential 
terms of the agreement are clear. Dow supplied the sili-
cone, and the ASPRS supplied the monitor and selected 
physicians to perform the experiment (called the investiga-
tors) . Dow and the ASPRS would jointly pay the expenses of 
the medical monitor. They would exercise joint control over 
all of the documents to be used in the study. Agreement by 
the ASPRS and Dow was required on "all pertinent documents, 
forms, manuals and patient releases." (Exhibit A, Paragraph 
12, R.1672). 
The following is a summary of the major aspects of 
the study over which the ASPRS and Dow were to share con-
trol : 
(a) Consent form (patient release); 
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(b) Medical monitor selection; 
(c) Investigators selection; 
(d) Medical monitor - payment; 
(e) Publications, panel appearances, seminars re: 
liquid silicone; 
(f) All pertinent documents, manuals, forms; 
(g) Medical monitor guide book (duties); 
(h) Training seminar for investigators; 
(i) Obtaining IRB approval; 
(j) Investigation location selection. 
3. Activities of Medical Monitor. 
Dr. Goldwyn was appointed by the ASPRS to be 
monitor of the injectable liquid silicone experiment 
(Goldwyn depo., R.1810, p.70, "I was asked by the president 
of ASPRS"). Goldwyn's duties as monitor are partially set 
forth in a letter from Arthur Rathjen (Dow Medical Liason) 
to Ross Musgrave (ASPRS). These duties include: 
1. Act as Faculty Dean in training the inves-
tigators in the study; 
2. Approve the admission of each patient into 
the experiment; 
3. Answer inquiries from investigators regarding 
problems; 
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4. Be the initial contact regarding complica-
tions; 
5. Assist in biannual reports to the FDA; 
6. Make monthly reports to Dow on patient 
treatment; 
7. Review any submission to the FDA relating to 
the safety and efficiency of injectable 
liquid silicone. 
(See letter from Rathjen, 1/7/77, R.1628, attached as 
Exhibit D.) 
A critical duty which Goldwyn fulfilled was to 
help draft the consent form, (Rathjen depo., R.1812, p. 106 
". . . The informed patient consent [form] was . . . pre-
pared by Dr. Goldwyn and . . . the ASPRS . . . ") . This 
consent form had to outline "the hazards involved" with 
injectable liquid silicone. 21 C.F.R. §130.37(h) (1967). 
This consent form was the one used to obtain Celia's consent 
to the treatment. (Celia Anderson depo, R.1811, Depo. 
Exhibit 1, Exhibit E to this brief.) 
The protocol which controlled the silicone experi-
ment also defines the monitor's duties by reference to 
federal regulations (Protocol, 9/2/77, p.2, R.1630, 
"[Goldwyn's] role as medical monitor will be that defined by 
FDA regulations.")! While these are not specifically 
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identified, presumably they had reference to the regulations 
proposed in 1977 defining a monitor's role. Under these 
regulations, a monitor must "assure that the investigator 
understands the investigational status of the test article, 
understands the nature of the protocol or investigational 
plans and controls, and understands and accepts his obliga-
tions in conducting the clinical investigation . . . " 42 
Fed.Reg- No. 187, p. 49623 (9/27/77). After the investiga-
tion begins, the monitor assures the investigator's "adher-
ence to the protocol," "maintenance of adequate records," 
and "timely, adequate and accurate" reporting. _Id. at 
49624. The monitor "shall be available monitor shall act as 
the liaison and communication link between the sponsor [Dow 
and the ASPRS] and the investigator." Id. 
Goldwyn performed each of the above duties with 
regard to Celia Anderson. Only Dr. Goldwyn could authorize 
Celia's injection with liquid silicone. Dr. Woolf has 
testified: 
[Goldwyn] was the one who made the deci-
sion whether there was medical necessity 
for the injection. 
(Woolf depo., R.1813, p.29.) In deciding whether there was 
medical necessity to inject liquid silicone, Dr. Goldwyn 
reviewed Celia's medical history, her photographs, ensured 
that she had signed a consent form, reviewed Celia's patient 
6 
form, her laboratory data, and her x-rays. (Goldwyn depo., 
R. 1810, pp.30-34.) Based on his review, Goldwyn diagnosed 
Celia as having severe lipodystrophy (loss of fat in the 
face), and specifically approved Celia for injection with 
injectable liquid silicone. (Goldwyn depo., R.1810, 
pp.110-11; Goldwyn letter, 4/19/78, R.1652.) 
Goldwyn also had the responsibility to oversee the 
training program that Dr. Woolf attended. Goldwyn taught the 
doctors (including Woolf) what the patient selection crite-
ria were. This training program was held in Ann Arbor, 
Michigan. 
After Goldwyn's approval, Celia received the 
experimental series of liquid silicone injections from 
Woolf. She suffered increasingly painful inflammation to 
her cheek. Eventually, she underwent major reconstructive 
surgery to partially remove the silicone embedded in her 
face. 
When Celia began to show an adverse reaction, Dr. 
Woolf reported to Goldwyn. Thereafter, Woolf regularly 
updated Goldwyn on Celia's treatment, (R.1633 to 1652). 
This continued for several years. At a later stage, Dr. 
Leonard replaced Dr. Woolf as the treating physician. How, 
Dr. Leonard reports to Goldwyn on Celia's status. 
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4. Actual Control of ASPRS Over the Study. 
The ASPRS in fact exercised joint control over the 
administration of the study. The ASPRS selected the inves-
tigators who would inject liquid silicone, (Rathjen depo. , 
R.1812, p.102; Goldwyn depo., R.1810, pp.60,116). Of 
course, this included Dr. Woolf. The ASPRS chose the 
medical monitor, Dr. Goldwyn. (Goldwyn depo., R.1810, p.70; 
Rathjen depo., R.1812, p.102.) The ASPRS ensured that the 
investigators obtained approval from an Institutional Review 
Board (a committee of professional and lay persons who 
oversee experimental research). (Rathjen depo., R.1812, 
p.102.) Most importantly, the ASPRS helped draft the 
consent form. (I^ « p.102.) In summary, the ASPRS was to 
"police" the study. (Id. p.103.) 
The ASPRS was held out as a co-sponsor or joint 
sponsor of the liquid silicone experiment. For example, the 
letter sent to Dr. Woolf outlining the experiment represent-
ed the training seminar and "investigational program" as 
jointly administered by the ASPRS and Dow. (See 9/26/77 
letter of Dow, R.1686, Exhibit D.) As Arthur Rathjen 
testified that the ASPRS was a joint sponsor of the liquid 
silicone program. 
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5. ASPRS and Goldwyn Actions Directed Toward Utah. 
The ASPRS and Dow jointly participated in select-
ing the geographic locations for the injection of liquid 
silicone. The actual selection was made by Dr. Peterson, 
President of ASPRS, and Dallas Whaley, Executive Vice 
President of the ASPRS. Salt Lake City, Utah was specifi-
cally selected as a location for liquid silicone injection. 
Dr. Woolf, a Utah doctor, was chosen by the ASPRS to inject 
liquid silicone in Utah. (Woolf depo. R.1813, p.6-7.) 
Thus, the ASPRS knew that the consent form it 
helped draft would be sent to Utah, and used by a Utah 
doctor, (a member of the ASPRS) to explain liquid silicone 
injections to a Utah patient. The investigators materials 
were probably prepared at least in part by the ASPRS. This 
material was used to inform Dr. Woolf of the nature, hazards 
and risks of injectable liquid silicone. 
Goldwyn knew when he became monitor that he would 
be approving silicone injections of patients in Utah. He 
helped draft the consent form he knew would be sent to those 
Utah patients. He oversaw the training given to the Utah 
doctor who was to inject those patients. 
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6. Defects in the Consent Form. 
Celia suffered a severe chronic inflammatory 
reaction to the liquid silicone. The risk of such a reac-
tion was well known to Dow and ASPRS. (Rule 56(f) Affidavit 
of Daniel Bertch, R.1590.) Previous patients injected with 
liquid silicone had a reaction to silicone severe enough to 
require surgery. Id. The only disclosure of that risk in 
the consent form is the statement that surgical removal may 
be required if Celia's body "does not tolerate" silicone. 
What the word "tolerate" means is not explained, nor is the 
suffering which accompanies such a reaction explained. 
Furthermore, the ineffectiveness of surgical 
removal was admitted by Dow to the F.D.A. (Ld. at 1608.) It 
is impossible to remove all the injected silicone, and the 
body continues to react to the silicone left after surgery. 
Of course, surgical removal may leave severely disfiguring 
scars or require restoration of the removed tissue by skin 
grafts. This is not explained in the consent form. 
Finally, the consent form implies that the inject-
ed silicone can be removed by needle (aspiration). Of 
course, that is impossible. 
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SUMMARY OF ARGUMENT 
AT POINT I 
Because the trial court ruled on in personam 
jurisdiction based on documentary materials, depositions and 
affidavits, Celia need only make a prima facie showing of 
personal jurisdiction. All facts and inferences are 
considered most favorably to Celia. 
AT POINT II 
Celia's allegations that Goldwyn and the ASPRS 
caused her injury in Utah should have been accepted as true. 
Because there was evidence in the record to support a 
finding of causation, the trial court's preliminary decision 
deprived Celia of a trial on the merits of causation. 
Furthermore, because the ASPRS was a joint 
adminstrator of the experiment with Dow, Dow's contacts with 
Utah should be imputed to the ASPRS. 
AT POINT III 
The ASPRS chose Salt Lake City as an experiment 
site, selected a Utah ASPRS member to do the experiment, and 
otherwise jointly supervised the experiment. It has a 
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substantial connection with Utah sufficient to satisfy 
federal due process. 
AT POINT IV 
As a medical monitor, Goldwyn made a decision to 
enter Celia in the experiment. He helped draft the consent 
form used to inform Celia of the risks in the experiment, 
and monitored her entire treatment. Goldwyn has continuing, 
substantial obligations with Celia sufficient to show 
purposeful availment of Utah law. 
ARGUMENT 
POINT I 
ALL FACTS AND INFERENCES MUST 
BE DRAWN MOST FAVORABLY TO PLAINTIFF 
The trial court ruled on in personam jurisdiction 
based on documentary materials, depositions and affidavits 
supplied by the parties. "If jurisdiction is decided solely 
on the basis of written materials, the plaintiff should be 
required only to make a prima facie case of jurisdic-
tion . . . ." Welsh v. Gibbs, 631 F.2d 436, 438 (6th Cir. 
1980). To show a prima facie case of jurisdiction, plain-
tiff need only "demonstrate facts which support a finding of 
12 
jurisdiction in order to avoid a motion to dismiss." Data 
Disc, Inc. v. Systems Tech. Assoc. , Inc., 757 F.2d 1280, 
1285 (9th Cir. 1977) . 
In deciding whether a prima facie showing of 
jurisdiction has been made, ". , . the court must construe 
the affidavits and pleadings most strongly against the 
moving party, with conflicts resolved in favor of plain-
tiffs." Seqil v. Gloria Marshall Mqt. Co., Inc., 568 F.Supp. 
915, 917 (D. Utah 1983) (J. Aldon Anderson). Accord, see: 
Welsh v. Gibbs, 631 F.2d 436 (6th Cir. 1980); Data Disc, 
Inc. v. Systems Tech. Assoc, Inc., 557 F.2d 1280 (9th Cir. 
1977); DeMelo v. Toche Marine, Inc., 711 F.2d 1260 (5th Cir. 
19 8 3) ; Visual Sciences, Inc. v. Integrated Comm., Inc., 660 
F.2d 56 (2nd Cir. 1981); Neiman v. Rudolf Wolff & Co., Ltd., 
619 F.2d 1189 (7th Cir. 1980); Ten Mile Industrial Park v. 
Western Plains Service Corp., 810 F.2d 1518 (10th Cir. 
1987). Compare Beck v. Farmers Ins. Exch., 701 P.2d 795, 
802 (Utah 1985) . 
A court may not "weigh" opposing affidavits, 
except in the rare case where an affidavit is inherently 
13 
incredible. Data Disc, Inc v. Systems Tech. Assoc./ Inc., 
supra, 557 F.2d at 1284.1 
An appellate court reviews de novo a question of 
prima facie in personam jurisdiction : 
The appellate court, in reviewing the 
documentary evidence presented, is in as 
good a position as the district court to 
determine whether appellants have made a 
prima facie showing of personal juris-
diction. We therefore, believe it is 
appropriate to review the district 
court's ruling under the non-deferential 
de novo standard. See Hohri v. United 
States, 782 F.2d 227, 241 (D.C. Cir. 
1986) (applying "independent review" 
standard to district court's determina-
tion of subject matter jurisdiction 
based on documentary evidence outside of 
pleadings). 
Ten Mile Industrial Park v*. Western Plains Service Corp., 
supra., 810 F.2d at 1524. Compare also Management Committee 
v. Graystone Pines, Inc., 652 P.2d 896 (Utah 1982) (de novo 
review of trial court's grant of directed verdict); Betenson 
v. Call Auto & Equip. Sales, Inc., 645 P.2d 684 (Utah 1982) 
(de novo review of trial court's grant of summary judgment). 
l()f course, if the court cannot rule as a matter of law 
that there is no jurisdiction, the plaintiff must still go 
forward with evidence at trial which is sufficient to 
establish jurisdiction. 5C Wright & Miller, Fed. Prac. and 
Proc., §1350 at p.558 (1969). 
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POINT II 
THE CONDUCT OF THE ASPRS AND GOLDWYN FALLS 
WITHIN THE REACH OF UTAH'S "LONG ARM" STATUTE 
1. Causing Tortious Injury in Utah. 
Utah can exercise jurisdiction over persons who 
cause any tortious injury within Utah. Utah Code Ann., 
§78-27-24(3) (1969). Celia's complaint alleges an injury 
caused within Utah by a consent form drafted by Goldwyn and 
the ASPRS. Celia's claim is that the consent form failed to 
adequately inform her of the risks involved in the experi-
mental injections.2 Celia also claims that Goldwyn caused 
her injury by negligently admitting her to the experiment. 
Finally, the ASPRS caused her injury by its negligent 
supervision of Woolf's training and I.R.B. approval. The 
^Celia may proceed against the drafters of the consent 
form (ASPRS, et al.) as a foreseeable third-party expected 
to rely on it. Salt Lake City School Dist. v. Galbraith & 
Green, Inc., 740 P.2d 284 (Utah Ct. App. 1987). 
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trial court found that neither Goldwyn nor the ASPRS caused 
injury in Utah. 
The consent form was the principal source of 
information for Celia regarding the risks of experimental 
injections. Indeed, Dr. Woolf testified that he simply read 
the consent form to Celia. (Woolf depo, R.1813, p.59.) 
ASPRS and Goldwyn argued below that the consent 
form was not causally related to Celia's injuries. Indeed, 
their reply memorandum states: "The consent form did not 
create any risk of injury. The consent form was merely a 
document by which an individual could manifest consent to 
participate . . . " . However, courts and commentators do 
not share this cynical view of informed consent. See 
generally, Deigado and Leskovac, Informed Consent in Human 
Experimentation: Bridging the Gap Between Ethical Thought 
and Current Practice, 34 U. C . L. A. Law Rev. 6 7 (1986); 
Barson by Barson v. E.R. Squibb & Sons, Inc., 682 P. 2d 832 
(Utah 1984). More importantly, Celia has alleged that she 
would not have entered the experiment if a full disclosure 
of the risks had been made. (R.1576.) This allegation 
should be taken as true for purposes of determining whether 
a prima facie case of jurisdiction is shown. 
Celia also claims that Goldwyn caused her injuries 
by negligently admitting her to the experiment. . If Goldwyn 
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had not admitted Celia to the program, she would not have 
had the injection and resulting injuries. 
The ASPRS also assumed a joint duty with Dow of 
ensuring that the investigators had I.R.B. approval. In 
Celia's case there was no effective oversight by an I.R.B. 
committee. Indeed, it appears that there may have been none 
at all. The I.R.B. is regarded as the "principal mechanism" 
for insuring adequate informed consent in experimental 
research. Informed Consent in Human Experimentation . . . , 
supra, 34 U.C.L.A. L. Rev. at 69. If a functioning I.R.B. 
had been in place, Celia would have received full informa-
tion regarding the risks involved. She alleges that if she 
had received full disclosure, she would not have entered the 
experiment. 
The ASPRS and Goldwyn made the additional argument 
that they did not participate in drafting the consent form, 
and they did not jointly administer the experiment. Howev-
er, there was other evidence in the record that the ASPRS 
did help prepare the consent form, and did jointly adminis-
ter the experiment. Celia was entitled to have her evidence 
accepted as true for jurisdictional purposes. 
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2. Jurisdictional Issues are Common to Negligence Issue. 
Celia is obligated to prove causation between the 
adequacy of disclosure and her decision to undergo the 
injections. At the same time, she must show that Goldwyn 
and the ASPRS "caused" injury in Utah by the inadequacy of 
the consent form they drafted. The issue of causation is 
common to negligence and in personam jurisdiction. 
Celia also has to show that Goldwyn's decision to 
admit her to the experiment was a proximate cause of her 
injury. For jurisdiction, she must show that Goldwyn's 
decision caused injury in Utah. This issue is common to 
both jurisdiction and negligence. 
If the jurisdictional question is "tied to the 
actual merits of the case," the final jurisdictional deter-
mination should be postponed until trial "to prevent a 
summary decision on the merits without the ordinary inci-
dents of a trial including the right to a jury." Schramm v. 
Oakes, 352 F.2d 143, 149 (10th Cir. 1965). When the trial 
court concluded that the consent form and Goldwyn's approval 
of silicone injections did not "cause" injury, it deprived 
Celia of the right to have jury trial on the issue of 
causation. 
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3. As Joint Sponsors of the Study, the Contacts of Dow 
Corning with Utah are imputed to the ASPRS. 
Dow Corning has not disputed the existence of its 
minimum contacts with Utah arising out of the liquid sili-
cone experiment. It could hardly dispute this, for it 
shipped liquid silicone to Utah knowing it would be injected 
there Lnto Celia Anderson. 
Celia has alleged a joint venture between the 
ASPRS and Dow Corning in the sponsorship and administration 
of the liquid silicone experiment. (Second Amended Com-
plaint, paragraph 5, R.1565.) "Joint ventures, like 
partnerships, are jural entities, and are treated as such 
for jurisdictional purposes." Aigner v. Bell Helicopters, 
Inc., 86 F.R.D. 532, 540 (N.D. 111. 1980) citing in support 
First Nat'l Bank of Minn, v. White, 420 F.Supp. 1331, 1335 
(D. Minn. 1976). The Aigner court further explained: 
. whenever one co-venturer acts in 
the forum to further the interests of 
the venture, his contacts with the same 
will, for purposes of personal jurisdic-
tion, also be attributed to his 
co-venturers. See First National Bank 
of Minneapolis v. White, supra at 1335. 
Consequently, when the related 
activities of one co-venturer in the 
forum are sufficient to sustain the 
exercise of jurisdiction, personal 
jurisdiction ordinarily will lie as to 
all of the co-participants in the 
venture. 
Aigner, supra, at 540. There was substantial evidence that 
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the ASPRS did jointly sponsor and administer the experiment. 
Celia was entitled to have that evidence accepted as true 
for purposes of making a prima facie showing of jurisdic-
tion. 
The existence of joint control or the existence of 
a joint venture is a disputed fact issue that a jury must 
decide. Rogers v. M.O. Bitner Co. , 738 P.2d 1029 (Utah 
1987); Strand v. Cranney, 607 P.2d 295 (Utah 1980). Because 
the liability issue overlaps the jurisdictional issue, the 
trial court's decision deprived Celia of a jury trial on the 
merits. Schramm v. Oakes, supra, 352 F.2d 143. 
POINT III 
UTAH MAY CONSTITUTIONALLY ASSERT 
JURISDICTION OVER THE ASPRS 
1. The ASPRS has Minimum Contacts with Utah. 
Jurisdiction over the ASPRS in Utah is proper if 
it has "purposefully availed" itself of Utah law. Hanson v. 
Denckla, 357 U.S. 235, 253, 78 S. Ct. 1228, 1239-1240, 2 
L.Ed.2d 1283 (1958). Purposeful availment is shown where 
actions of the ASPRS "create a 'substantial connection' with 
the forum State. [Citations omitted]." Burger King Corp. 
v. Rudzewicz, 471 U.S. 462, 475; 105 S.Ct. 2174, 2184; 85 
L.Ed.2d 528 (1985). A substantial connection is present 
where a defendant's "efforts are purpos€> fully directed 
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toward residents of another state." (Emphasis added). 
Asahi Metal Ind. v. Sup. Ct. of Cal. Solano Cty. , U. S. 
; 107 S.Ct. 1026, 1033 (1987).3 
The ASPRS has purposefully directed its activities 
toward Utah. The ASPRS carefully selected Utah as a site 
for liquid silicone injections. Furthermore, they selected 
a Utah doctor who was a member of the ASPRS to do the 
injection. Thus, their connection with Utah cannot be 
reyarded as the result of the "unilateral activity of 
another party or a third person," Helicopteros Nacionales de 
Colombia, S.A. v. Hall, 466 U.S. 408; 104 S.Ct. 1868, 1872; 
80 L.Ed.2d 404 (1984), nor can it be regarded as "random," 
"fortuitous" or "attenuated." World-Wide Volkswagen Corp. 
v. Woodson, 444 U.S. 286; 100 S.Ct. 559; 62 L.Ed.2d 490 
(1980). 
Furthermore, the ASPRS helped draft the consent 
form knowing that it would be used in Utah, the place it had 
chosen, by Dr. Woolf, the ASPRS doctor whom it had selected 
to treat Utah patients. This purposeful direction of 
activities toward Utah is sufficient to allow jurisdiction 
•^ Because Celia's injury does arise out of ASPRS' 
contacts with Utah, she need not show contacts of a 
"continuous and systematic nature" or that the ASPRS "does 
business" in Utah. 
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arising out of those activities. 
For example, in Jones Ent., Inc. v. Atlas Serv. 
Corp., 442 F.2d 1136 (9th Cir. 1971), an Oregon engineering 
firm submitted plans for a building to a subcontractor, 
knowing that the plans would be used in Alaska. In uphold-
ing jurisdiction, the court rejected any distinction between 
sending defective "products" into a state, and defective 
"plans." 
Likewise, in Keeton v. Hustler, Inc., 465 U.S. 
770; 104 S.Ct. 1473; 79 L.Ed.2d 790 (1984), jurisdiction was 
exercised over a publisher sent libelous magazines into the 
forum state. And in Burt v. Bd. of Regents, etc., 7 57 P. 2d 
242 (10th Cir. 1985), Colorado jurisdiction v/as upheld in a 
suit over a libelous letter mailed by a Kansas doctor into 
Colorado. See also, Rice Growers Ass'n v. First Nat'l Bank 
of Minn., 214 Cal. Rptr. 468 (App. Ct. 1st Dist. 1985) 
(plans and specifications for ship); McGee v. International 
Life Ins. Co., 355 U.S. 220; 78 S.Ct. 199; 2 L.Ed.2d 223 
(1957) (life insurance policy). 
Most importantly, the ASPRS voluntarily undertook 
joint administration of a medical experiment involving 
patients in numerous states. "In undertaking interstate 
business [a defendant] must recognize and accommodate . . 
the probability and necessity of litigating in foreign 
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forums." Mallory Enq. v. Ted R, Brown & Assoc, 618 P. 2d 
1004, 1008 (Utah 1980); see also Synergetics v. Marathon 
Ranching Co. Ltd. , 701 P.2d 1106, 1111 (Utah 1985). Thus, 
it is not unforeseeable or unreasonable for the ASPRS to be 
haled into courts in states such as Utah where those 
patients were treated. 
2. Jurisdiction over the ASPRS is consistent with fair 
play and substantial justice. 
After it has been decided that a defendant has 
minimum contacts, the Court may consider other factors to 
determine if the exercise of jurisdiction would comport with 
fair play and substantial justice. Burger King, supra, 471 
U.S. at 476; 105 S.Ct. at 2184. These factors include the 
burden on defendant, the forum state's interest in adju-
dicating the dispute, the plaintiff's interest in obtaining 
convenient and effective relief, and the interstate judicial 
system's interest in obtaining the most efficient resolution 
of the controversy. Id. 
The most effective and efficient place to litigate 
Celia's claim is in Utah. Both Dow and Dr. Woolf are 
presently defending in this forum. Utah has an interest in 
providing one of its citizens with a forum in which to seek 
relief for experimental treatment performed in Utah. Celia 
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has local counsel and nearly every witness will be from 
Utah. 
If Celia is forced to litigate in Illinois, she 
will be faced with the possibility of Goldwyn pointing the 
finger at Dow and the ASPRS, with Dow and Woolf pointing the 
finger (in Utah) at Goldwyn. Furthermore, an Illinois court 
will probably be faced with applying Utah law. All these 
factors add weight to allowing litigation of this matter in 
Utah. 
POINT IV 
UTAH MAY CONSTITUTIONALLY ASSERT 
JURISDICTION OVER GOLDWYN BASE!) 
ON HIS RELATIONSHIP WITH UTAH" 
1. Physical presence in a State is not necessary to create 
minimum contacts. 
A person may have minimum contacts with a 
state without ever physically entering it. "Jurisdic-
tion . . . may not be avoided merely because the defendant 
did not physically enter the forum State." Burger King 
Corp. v. Rudzewicz, supra 471 U.S. at 476, 105 S.Ct. at 
2184, 85 L.Ed.2d 528 (1985). (Emphasis in the original.) 
Thus, the fact that Goldwyn has never been to Utah is not 
dispositive. 
24 
2. Purposeful Availment of Utah Law by Goldwyn. 
Goldwyn may be sued in Utah if he has "purposeful-
ly availed" himself of Utah law. Hanson v. Denckla, 357 
U.S. 235, 253, 78 S. Ct. 1228, 1239-1240, 2 L.Ed.2d 1283 
(1958) . 
Purposeful availment by Goldwyn is shown where his 
contacts with Utah proximately result from actions by 
Goldwyn that "create a 'substantial connection' with the 
forum State. [Citations omitted]." Burger King, supra, 471 
U.S. at 415; 105 S.Ct. at 2184. A substantial connection is 
present where a defendant's "efforts are 'purposefully 
directed' toward residents of another state . . . " (Emphasis 
added.) Id) Asahi Metal Inc. v. Sup. Ct. of Cal., Solano 
Cty. , U.S. ; 107 S. Ct. 1026, 1033 (1987). On 
the other hand, jurisdiction is not proper if the only 
contact with the forum state is a result of the "unilateral 
activity of another party or a third person." Helicopteros 
Nacionales de Colombia, S.A. v. Hall, 466 U.S. 408, 413; 104 
S.Ct. 1868, 1873; 80 L.Ed.2d 404 (1984). 
The purposeful availment necessary to support 
jurisdiction may be found, 
where the defendant 'deliberately' has 
engaged in significant activities within 
a State, Keeton v. Hustler Magazine, 
Inc. , 465 U.S. at , 104 S.Ct. 
at , or has created 
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continuing obligations between himself 
and residents of the forum, Travelers 
Health Ass'n v. Virginia, 3 39 U.S. at 
648, 70 S.Ct. at 929. 
Burger King Corp., supra, 471 U.S. at 475-476; 105 S.Ct. at 
2184 (emphasis added.) Thus, if Goldwyn "has created 
continuing obligations between himself and residents of the 
forum," i.e. Celia, a substantial connection with Utah is 
present, and jurisdiction may be asserted. 
Goldwyn purposefully created "continuing relation-
ships and obligations" with Utah patients when he stepped 
into the role of monitor. The relations and obligations he 
undertook were substantial. He assumed a fiduciary duty to 
each patient in Utah to comply with the protocol, to proper-
ly train their doctor, to accurately diagnose them, to use 
care in authorizing silicone injections to them, and to 
adequately follow their treatment. In short, Goldwyn's 
substantial contacts arise out of his purposeful decision to 
monitor a multi-state medical experiment which he knew 
included Dr. Woolf in Utah. 
Goldwyn's contacts do not arise out of the unilat-
eral activity of Celia. If Celia had treated in Massachu-
setts with Goldwyn, and then returned to Utah, Goldwyn's 
contacts with Utah would be the result of Celia's unilateral 
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activity. Of course, Celia never left Utah, and Goldwyn has 
had an ongoing interstate obligation and relationship with 
her for over 10 years, 
3. Long-arm jurisdiction as applied in malpractice ac-
tions . 
Celia's relationship with Goldwyn in some ways is 
analogous to a doctor-patient relationship* A patient who 
seeks out an out-of-state doctor, travels to that doctor's 
state, treats there, and returns home, may not thereafter 
sue the doctor in the patient's new state of residence. 
Wright v. Yackley, 459 F.2d 287 (9th Cir. 1972). However, 
if a doctor diagnoses a patient via telephone or by mail, 
while the patient is in his or her own state of residence, 
jurisdiction is appropriate. McGhee v. Riekhof, 442 F.Supp. 
1276 (D. Mont. 1978). Also, if an out-of-state doctor has a 
continuing duty to render treatment, the necessary substan-
tial connection for jurisdiction is present. S.R. v. City 
of Fairmont, 280 S.E.2d 712 (W.V. 1981). Wright itself 
teaches that: 
The balance of factors involved in a due 
process determination might be different 
if a doctor could be said to have 
treated an out-of-state patient by mail 
or to have provided a new prescription 
or diagnosis in such fashion. In that 
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event, the forum state's interest in 
deterring such interstate medical 
service would surely be great. 
Wright v. Yackley, supra, 459 F.2d'at 289, n.4. See also, 
Trail and Maney, Jurisdiction, Venue and Choice of Laws in 
Medical Malpractice Litigation, 7 J. Legal Med. 403, 420-421 
(1986). 
This distinction is clearly illustrated by compar-
ing the facts of Wright with the facts of McGhee. In 
Wright, a South Dakota resident treated with a South Dakota 
physician. The doctors prescribed certain drugs for the 
patient. Thereafter, the patient moved to Idaho. While in 
Idaho, the patient asked for, and received, a copy of that 
South Dakota prescription to fill in Idaho. The South 
Dakota doctor mailed a copy of the prescription previously 
given in South Dakota to the patient now residing in Idaho. 
The Idaho District Court found no jurisdiction. 
However, in McGhee, the Montana patient was given 
a new telephone diagnosis by a Utah surgeon. This diagnosis 
was given while the patient was in Montana. This continua-
tion of the doctor-patient relationship after the patient 
had left the doctor's state of residence was considered the 
key that allowed jurisdiction. 
Goldwyn diagnosed Celia Anderson by mail as having 
severe lipodystrophy. Celia never left the State of Utah, at 
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any time during his diagnosis. This distinguishes Celia's 
case from Wright and the other cases which follow it. In 
fact, Celia's case presents a far stronger case for personal 
jurisdiction than does McGhee. The McGhee plaintiff 
traveled to Utah to treat, and was injured by negligent 
follow-up care after he returned to Montana. However, Celia 
never went to Massachusetts or anywhere else to treat. Her 
entire course of silicone treatment was done in Utah. 
4. Jurisdiction over Goldwyn is consistent with fair play 
and substantial justice. 
After it has been decided that a defendant has 
purposefully established minimum contacts, the Court may 
consider other factors to determine if the exercise of 
jurisdiction would comport with fair play and substantial 
justice. Burger King, supra, 871 U.S. at 476; 105 S.Ct. at 
2184. These factors include the burden on defendant, the 
forum state's interest in adjudicating the dispute, the 
plaintiff's interest in obtaining convenient and effective 
relief, and the interstate judicial system's interest in 
obtaining the most efficient resolution of the controversy. 
Id. 
The most effective and efficient place to litigate 
is in Utah. Both Dow and Dr. Woolf are presently defending 
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in this forum. Utah has an interest in providing one of its 
citizens with a forum in which to seek relief for 
experimental treatment performed in Utah. Celia has local 
counsel and nearly every witness will be from Utah. 
If Celia is forced to litigate in Massachusetts, 
she will be faced with the possibility of Goldwyn pointing 
the finger at Dow and the ASPRS, with Dow and WooIf pointing 
the finger (in Utah) at Goldwyn. Furthermore, a Massachu-
setts court will probably be faced with applying Utah law. 
All these factors add weight to allowing litigation of this 
matter in Utah. 
CONCLUSION 
1. Jurisdiction over Goldwyn. 
Only Goldwyn could approve the injection of sili-
cone into a patient. He was not a consultant who merely 
gave advice nor an administrator who merely checked to see 
that the paperwork was in order. On the contrary, the 
decision whether to inject a patient with liquid silicone 
was only made by Dr. Goldwyn after he exercised his own 
professional and scientific judgment. Celia could only be 
injected if Goldwyn diagnosed her as having severe 
lipodystrophy. Goldwyn made that diagnosis, and Celia was 
injected with liquid silicone. 
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The fact that Goldwyn has never physically entered 
Utah is not controlling. The Burger King court stated, "We 
have consistently rejected the notion that an absence of 
physical contacts can defeat personal jurisdiction there. 
[Citations omitted]." Id. 471 U.S. at 476; 105 S. Ct. at 
2184. 
Furthermoref "parties who 'reach out beyond one 
state and create continuing relationships and obligations 
with citizens of another state' are subject to regulation 
and sanctions in the other state for the consequences of 
their activities. [Citations omitted]." Id., 471 U.S. at 
472; 105 S.Ct. at 2182. Goldwyn created extensive obliga-
tions to Dr. Woolf and his Utah patients when he decided to 
be the monitor. Goldwyn entered interstate activity by 
agreeing to monitor a multi-state medical experiment. 
Because he voluntarily accepted interstate obligations and 
responsibilities to Dr. Woolf and Celia in Utah, Utah 
jurisdiction over him is proper, appropriate and constitu-
tional • 
2. Jurisdiction over the ASPRS. 
The ASPRS was not an advisory board which gratui-
tously dispensed advice. It was an active participant and a 
co-sponsor of the study. The injection of liquid silicone 
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in Salt Lake City was not happenstance, but instead the 
result of careful, specific planning by the ASPRS. The 
ASPRS selected one of its own in Utah to do the injections. 
It helped draft the consent form, and jointly administered 
the training program for Dr. Woolf. It was a full partner 
in every sense of the word with Dow in the administration of 
the liquid silicone experiment. The ASPRS engaged in 
interstate activity by co-sponsoring and administering a 
multi-state medical experiment which included a Utah doctor 
and Utah patients. Exercising Utah jurisdiction over it for 
those interstate activities is proper, appropriate and 
constitutional. 
3. Relief Sought on Appeal. 
Celia seeks a ruling from this Court that the 
district court had in personam jurisdiction based on the 
materials before it. Alternatively, she seeks a remand with 
directions to determine personal jurisdiction after trial. 
DATED this j $ day of ?yfc4/?Mj£&U , 1988. 
ROBERT J. DERKY & ASSOCIATES 
Attorneys for Plaintiff 
ROBERT J. DEBRY 
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ADDENDUM 
EXHIBIT A: ASPRS Minutes of 4/18/77 
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EXHIBIT C: Dow Reply Minutes 5/18/77 
EXHIBIT D: Rathjen letter 1/7/77 
EXHIBIT E: Consent Form 
EXHIBIT A 
A L U A N Y P L A S T I C S T l * G TONS A S S O C I A T E D , T\ C. 
>^Z S> HC5PITAL OROf££SlONAL BJ 'LD iNC 
22 M A C K n 2 0 L ' L £ V A P D 
f A. E L L I O T J - . M 3 
ACS C H O £ H N M 2 
vEBSTER S T A ^ M A N in M D 
WORK COPY 
A»CA Cose: 51 8 
NEGOTIATION RE: DYMASN. L PROJECT 
American Society of Plastic 5 Reconstructive Surgery Inc. (ASPRS) 
and Dow Corning Corporation (DCC) 
March 24, 1977 
2:15 p.m. - 5:15 p.m. 
REPRESENTING A5PRS ; 
Rex Peterson, M.D. 
Peter Randall, M.D. 
Ross Musgrave, M.D. 
Ray Elliott Jr., M.D. 
Dallas Khalev 
Century Plaza Hotel 
Los Angeles, California 
1/ 
President ASPRS 
President-elect ASPRS 
Chnirmnn ASPRS Injectable Silicone Project 
Advisory Committee (ISPAC) 
Vice-Chairman ASPRS ISPAC 
Executive Vice President ASPRS 
REPRESENTING DOW CORNING CORPORATION J 
Ira Hutchinson 
i~ Rathj en 
Frank Hurley ?hd 
Former Business Mgr. DCC Medical Products 
Division; Consultant 
Senior Clinical Research Specialist; 
Medical Products Division, DCC. 
DCC's Biostatistic and Compjter Consultant 
for IND/NDA data; employee of 3iometri 
Research Institute, Washington, D.C. 
* -r o - eacn o: tne representatives was mtrocucec anc :::er.:::]eo, 
Dr. Peterson began the meeting with a statement that described ASPRf 
willingness and desire to cooperate with DCC to develop * meaningfu' 
project. He identified Dr. Elliott as the principle ncp:i?.tor 
.
 ? ^ ^ indicated that the name of the ASPRS Comi?;7*ee for i or A. 
ec .s new r c and I n j e c t a b l e S i l i c o n e h a d b e e n c h a n g e d to that it wou l d be k n o w n as the I n i e c t a b l e S i l i c o n e P r o i e c t A d v i s o r y 
C o m m i t t e e ( I S P A C ) . 
kd h i m s e l f n> the p r i n c i p l e n e g o t i a t e ^ for Mr . R a t h ; •::. i d e m i : 
Dow C o r n i n g and s:ated the p u r p o s e of the p r o j e c t . iie stated that 
DCC has no p l a n s at p r e s e n t to m a r k e t Dvmasy_l_beca_use_£ r.eI f-a-h 1 e 
meth o d for con: ::] of the ..product has n o : _ 'oc e rT'd c v e_l oped . A l : hong}1 
tTTere r r :u*' PTg^rettec c o m m e r c i a l future for eke dru-g-, D D C v/ould 
like to d e v e l o p s r r c g r a r that w o u l d ma) e the fluid a v a i l a b l e on 
2 l i m i t e d , n o n - p r o f i t b a s i s for the t r e a t m e n t of a d e f i n e J proup or pat:e~-
»--C r.ww a* 
c* i e c: s ** Ti e r e c : ' r r t n e r a p e u 11 c *~ n ". n 
It v ruI J r e q u i r e a s p e c i a l , * : * . ^ t 
.AS'IC ^ r P-::CNS*--;" .: < r ^ * C - N C T 3 sj-:i£~v 
7ILiv,fservice INDll^toAnake the fluid available i^r this I iTrpjced-
therapeutic use. He emphasized that DCC considered this aClltherapeut: 
profraa"'under strict"controlt"not an extension of the previous 
Tese^rch investigation. He would welcome a new name for the program 
and urged ASPRS to help select an appropriate one. 
As the negotiations developed, many, areas and topics of concern were 
identified and explored. ^ Agreement was reached in every instance, 
essential features of the program are: 
• " ' ^c^ fol ^--^ -frcod-*^ ' 
1. Purpose of Pro^rgjp-r^ 
^TT/C^Tr^tme^j^^x cases of severe facial defect for which no 
<TcHlHF~:reasonable treatment is available to yield a com-
parable (or better) result, 
b. A non-profit service to these select patients. 
Length of Program 
a. Therapeutic program: 3 years, maximum. 
b. New p a t i e n t s : first 2 years only"! 250/yr. maximum. 
c. Followup: 10 years minimum. - * (^  
NOTE: 1_. D C C {w_i 11 not p i a n jf,t"o market Dymasyl during the — * -
-^/.f^  \ treatment and followup period. 
^ {s=£$2.( No other therapeutic programs with Dym; 
T"/^^"^^^ \ ^ be started during this period without j 
asyl will 
J^SPRS/TXIC 
= ^ji. = i.u. (PDA approval would be ;tanclflory . ) 
JZZ reserves 
• c. er-O'; 
. m • ignt to v:tndrav rr 
retrain if untoward expense is noted. 
Uitt t U C 
casual coserve 
facial defects evident to the 
conversational length. 
-I iOiOH' . i not De oasis for exclusion. 
De 
gaugf 
Subjective and psychological complaints will nc 
basis for ijn c 1 u s i o n . 
Volumetric minimurr.s will be used as an obiecti^ 
or seve ""11"»'. 
A retrospective evaluation of the site and type of defects 
treated by the prev i o u s NDA in v e s t i g a t o r s will be used to 
find other valid objective criteria for case selection, 
2nd to serve as a guide to determine p r o b a b l e caseload 
of significant defects. 
No wrinVles or frown lines will be treated. 
The 'k-cicLil Monitor will approve all cases before treat-
based on h i s t o r y , physical f i n d i n g s , standard photo-
phs , and evidence of patient acceptance of the conditic 
t n e r r c t o c o I . 
j.:r ;i L 
Medical Monitor 
a. Many fine persons were considered for this important job 
^ b. The Medical M o n i t o r cannot inject liquid silicone. 
-. i* £ > X : "^e Medical Monitor will be paid directly by DCC for 
, yuJ^^ \ services rendered. Estimate 5.4500. - SO'OO'./year. 
d. Duties cf the Medical Monitor will be described in a' 
Guidebook :c be developed by DCC and approved by ASPRS. 
Assi "\~:nt of case? by region and caseload will be one 
O 1 h 2 c J U * *• •"* s 
vx< 
r,o oer* Go: jw n. o: ;• o s t o n 5.*iss. w n s s e l e c t e d 
lection of W c a t m e n t Team 
All previous investigators who qualify by new criteria 
will"be invited to participate in this program. 
he 7&aiiLJLUStJi3--JB£Tn^  — v l ksTKS 
All members of the Tcnm must be nffilinted with a Medical 
University or College on either the Full-Time or Clinical 
J L d i i -
The FDA requires a complete curriculum vitae from every 
member of the Team for their evaluation .and final approval 
Total number will not exceed 25. 
Geographic distribution will give regional coverage 
(10 - 12 regions). 
Team members may be selected to work in pairs in same 
office, institution, city, or region. 
ISPAC will select team. DCC reserves veto right. 
All members of the Team must agree to the strict protocol, 
and ethical code.developed for the program. 
aining of Treatment Team 
All members of the Team will be required to attend a 
training course regardless of previous experience. 
A detailed instruction Manual will be developed for 
the Treatment Team. 
Instructors will be Brs. Dingman, Murray, ?.ees , and 
31 a c k s m a . 
Reed Dingman, M.D. will be asked to be chairman of a 
course at Ann Arbor. . 
m e s oi Treatment Team 
All injections and examinations must be done by -a 
.named member of the Team, without exception. There can 
be no designation of these responsibilities to persons 
not identified to FDA. Every injector must have his 
curriculum vitae approved by the FDA and each injector 
must attend a scheduled training course as reGuested by 
< the FDA. 
All treatment must be non-profit. Any charges to the 
patient must fellow the guidelines (to-be developed in 
consultation with the Team and the Medical Monitor). 
Patients requesting treatment in this program will not 
ace eot e.c t r e a t m e n' a n v o t n e r c o n c 1 1 1 o n 
;o i n d i v i d u a l p u b l i c a t i o n s or p u b l i c exposure of any s o r t 
•elating to this prog m m will be permitted without the 
^ p r e s s e d apprc/al of PCC, ASPRS and the Medical Monitor. 
:-IUJ1 will be followed in evcrv detail. 
No ecticns wi be started on a Dotenti; new case/defe 
until all required studies have been completed and the 
patient has been accepted by the Medical Monitor. 
Liquid Silicone will net be injected into or made ava i1 ab1 
for any person, or for any condition, not approved by the 
All Liquid Silicone will be accounted for 
.n cetai. 
Discharge/Replacement of learn Members 
a. Medical Monitor: by agreement ASPRS/DCC 
b. Treatment Team: by agreement ASPRS/DCC, in consultation 
with Medical Monitor, for termination. ASPRS will name 
all replacements, subject to veto right of DCC. 
Thoughts on Drug Control 
a. D o s a g e v i a l 2 c c . m a x i m u m . 
b . N u m b e r e a c h v i a l 
c. E a c h v i a l i n i t i a l e d b y p a t i e n t a n d i n j e c t o r . 
d. Accurate dosage/treatment recorcs with strict accountabil 
e. Shipments from DCC will be based on estimates of injector 
-prior case approval by Medical Monitor is required. 
Pub: 
D. 
All publicity including, but t 1 ir n "> T ° f .0 , publications 
Duolic acoearan tr i> , p c j i n s n * l e 1 s
 7 nevs releases, e* must nave 
the prior approval of DCC/ASPPS, without 
The Medical Monitor, the Treatment Team, members of ASPRS 
and employees of DCC are all to be bound by this strict
 m 
policy. 
Two requested panel presentations were discussed and 
approved (Burlington VT. this Spring, and Southern Surgic 
in Dallas this P a l l ) . A description of the project will 
also aroear in the NEWSLETTER. 
Ccmmuni cation 
a. All correspondence between DCC, ASPRS and/or the Medical 
:• e copied to all three. ASPRS C O D V will £0 
D. 
C 
Monitor wil 
to cnairm* 
A summarv o: 
n z: ISPAC, and DCC copy will go to Mr. Rat 
il significant telephone conferences betwee 
any of the part:-:-? will be sent to all three, 
it is understood * h a t matters of p r i va t e privilege 
within DCC. and/or ASPRS wil] not require this communicati 
However, an open communication policy is urged wherever 
possible, and is mandatory in all matters directed to 
M; ical Monitor s ncocc l J) C l S. i 1 'ill a v o i d 
m i s u n c e r s t a n c : n : \c oromote a cooperative soiri' 
Legai rrooicns 
a. ASPRS and DCC will have independent legal advice on all 
o e r 11 n e n" 
b. ASPRS/DCC 
c . M e d i c a l - l o c a l 
n o t dec i dcJ . 
uocumen : s J«ifi :! U ^ i : orms 
w i l l be rev\ 
:• t : o n s an; 
nwi s 
mA 
anc patient reiezses 
on all of the above. 
malpractice issues were 
Miscellaneous 
a. The en t;r e schcdi::-;- o: dead] inc? has been moved back 
to permit time for selection of the Treatment Team and 
^reparation of the Protocol document. These should be 
The Training Course will be schedul.ee for late Set)t. or 
earlv Oct. 19 77. 
ne next mc 
•as scheduled 
in; r: \'S^S/?CC ~nd the Mc-d:cal Monitor 
'6 , 2 y 77 in Chi ca i;o , j incis 
The,meeting was adjourned at 5:15 p.m. FST after agreement by all 
.in~attendance that the cordial three hour session had provided 
the framework for s workable, humanitarian project. 
y 
Respectfully Suomitted, 
Ray A. Elliott Jr., M.D. 
ASPRS Negotiator 
Vice Chairman ISPAC 
April 8, 1977 
NOTE: Minutes were to be prepared by both Negotiators and circulat 
to the attendees for correction and comment. The final minutes 
would thus reflect the agreement of ASPRS/DCC with maximum accuracy 
EXHIBIT B 
April 11, 1977 
TO: Ray A. Elliott, Jr., M.D, 
Frank L. Hurley, Ph.D. 
Ross H. Musgrave, M.D. 
Rex A. Peterson, M.D. 
Peter Randall, M.D. 
Dallas F. Whaley 
FROM: A. H. Rathjen 
PROPOSED MINUTES FOR THE A.S.?.R.S./DOW CORNING COMBINED SILICONE 
INJECTION PROGRAM 
The meeting was held on Thursday, March 24, 1977, at 2:00-5:30 pm, 
It was held in the Senator's Conf. Room, Century Plaza Hotel, 
2025 Avenue of the Stars, Century City, Los Angeles, California. 
In attendance for A.S.P.R.S.: 
Rex A. Peterson, M.D. - President, A.S.P.R.S. 
Ross H. Musgrave, M.D. - Chairman, Silicone Injection 
Committee 
Ray A. Elliott, Jr., M.D. - Vice Chairman, Silicone Injectior 
Committee 
Peter Randall, M.D. - President-Elect, A.S.P.R.S. 
Dallas F. Whaley - Exec. Vice President, A.S.P.R.S. 
For Dow Corning: 
Ira Hutchison - Dow Corning, Representing Mel Nelson 
Frank L. Hurley, Ph.D. - Consultant for Dew Corning (Senior 
Partner, Biometric Research Institute, Washingtonr D.C.) 
Arthur H. Rathjen - Dow Corning 
Dr. Elliott was asked to chair the A.S.P.R.S. side for the meetinc 
A. Dr. Peterson began with introduction of personnel attending 
the meeting. Discussed February meeting in Scottsdale with • 
members of A.S.P.R.S., i.e. A. H. Rathjen' s/Dow Coming's 
proposed plan for implementation of Service IND. Plan had 
been reviewed, sentence by sentence, and conclusion was 
A.S.P.R.S. agreed with over-all concept. Nothing to change 
by Dow Corning. 
-,03*318 
Dr. Elliott: and Art Rathjen had met for 2-*~ hours on 
Saturday evening, March 19, and reviewed data and topics 
to be covered in March 24 meeting. 
Question by Dr. Elliott - For teaching symposium, who 
might be considered for faculty? Is it necessary to 
have all investigators as instructors? Suggestion by 
A. H.. Rathjen: 
a. Reed Dingman, M.D. 
b. Ralph Blocksma, M.D. 
c. Thomas Rees, M.D. 
d. Joseph Murray, M.D. 
All original seven plastic surgeon investigators will be 
asked to continue as investigators in new program if they 
so desire. Even though faculty will possibly be smaller, 
all seven investigators will be asked to be present at 
teaching symposium. 
Current contact with FDA Drug/Surgical Advisory Committee 
discussed. There is no active program being considered 
or underway with any other medical group or specialty. 
Indications for treatment under new program. 
a. Question of etiology - Is etiology important or the 
patient defect? Suggested that etiology be elimin-
ated, but establish conclusively that a patient only 
be considered as candidate "where or when no other 
reasonable treatment is available to give a compar-
able result." 
b. Trauma could be considered based on above criteria. 
Procram would be directed orimarilv to most critical 
cases of progressive facial hemiatrophy and 
lipodystrophy. 
c. Dr. Musgrave agreed that Dr. Dingmanfs definition of 
hemiatrophy and lipodystrophy was close to what is 
needed to determine patient's qualification for 
treatment. This definition is in writing. 
d. Indications for patient consideration and use will 
include proposed volumetric minimum. Volume minimum 
to be decided. 
e. Participation in Service IND will be limited to 
A.S.P.R.S. membership. "All new investigatcrs v;ill 
be trained. Dr. Peterson stated it is imperative 
j;.'-Sir* 
p a t i e n t rxurrJ>«r f o r o n e y e a r w o u l d b e 2 S 0 . 
g. Proposed list of A.S.P.R.S. candidates will be 
assembled by silicone injection committee, but 
Dow Corning has the privilege of veto. 
Dr. Musgrave indicated that he has received a total of 27 
inquiries relative to interested surgeons asking to be 
considered as investigators. 
Subject of investigator/injector affiliation. 
1. Discussion of pro and con on subject of major medical 
centers/departments, etc. vs. private practice and 
clinics. Suggestion that charges to patients be handled 
easier by private offices. This matter is recognizably 
more complicated than normal by donation of product and 
no charge of professional fee. However, ".fcstsic. lab tests, 
general physicals, photographs, etc. will J*?e. charged to 
the patient. 
2. Suggest that approved investigator b£ affiliated with a 
recognized medical center. 
3. There are several other very important points that must 
be clarified: 
a. Ethical limitations on publicity: 
(1) This will be handled by the Medical Monitor, 
Silicone Injection Committee, and Dew Corning. 
(2) No investigator will be a participant in any 
unilateral publicity, i.e. newspaper, radio, 
t.v., periodicals, or presentations ai: local or 
national medical meetings. 
b. A.S.P.R.S. members (Drsv Musgrave, Zllictt, Peterson, 
and Randall) did bridge-the subject of a signed 
document by the investigators relative to: 
(1) Indirect profit. 
(2) Direct fee and profit—suggested that a concensus 
be developed by investigators. 
(3) The spirit that this program cannot become self-
serving for the investigators. 
c. Dr. Elliott brought up the question of Medicaid— 
what is the law? Need an opinion on referrals and 
reimbursement expenses. 
d. Question of investigator suspension: 
1-^20 
(1) Ar*y ;r,v«s::c4:c: su.«;nri 10 possible iu$?«r.s:cft 
will be reviewed by Medical y.or.::or, Silicone 
Injection Committee, and Dow Corning. 
(2) Dow Corning is the recognized sponsor and must 
answer to F.D.A., will take the initiative if 
study protocol is violated or abused by individual 
investigators. Violators will be brought to 
attention of Medical Monitor. 
Subject of patient consent form. 
1. Dow Corning will assume responsibility of organizing 
content and offering a basic format. 
2. Dow Corning cannot assume responsibility for actual use 
with patient; Dow Corning cannot practice medicine! 
3. Drs. Elliott and Randall suggested at least a 10 year 
follow-up. Patient should sign agreement that they will 
cooperate by assuring yearly check-up. 
First attempt to identify regions and possible localities for 
investigators. A. K. Rathjen supplied for use at this meeting 
a large map (41 x 5!) of U.S. which was marked to identify: 
1. Locations of medical centers and residency programs in 
plastic and reconstructive surgery. 
2. Major areas for pooulation concentrations in descending 
order 1-50. 
3. Population areas where major medical centers were located. 
4. A. H. Rathjen was asked to identify, by red pins, loca-
tions of original investigators. 
5. A. H. Rathjen was asked to have map photographed for 
use by Silicone Injection Committee and Chicago office 
of A.S.P.R.S. 
6. A- K. Rathjen distributed to each meeting participant, 
a typed document which encompassed what was displayed on 
the map. 
7. In a very general and noncommitted way, Dr. Peterson and 
Dallas Whaley made a first attempt to identify areas/ 
regions that might be considered for location of investi-
gators. This list included: 
1. Portland/Seattle 
2. San Francisco 
•3. Los Angeles 
4. San Diego 
*;-.Q$2! 
6 . S a l t L^/ce C i t y 
7 . Denve r 
8. San Antonio - eliminated 
9. Dallas/Fort Worth 
10. Houston 
11. Kansas City 
12. Minneapolis/St. Paul 
13. Milwaukee/Madison 
14 . • Chicago 
15. St. Louis 
16. Memphis/Nashville 
17. New Orleans 
18. Indianapolis/Louisville/Cincinnati 
19. Atlanta 
20. State of Florida - location not defined 
21. Durham/Greensboro/Wir.s tcn-Salem 
22 . Norfolk/Richmond/Charlottesville 
23. Toledo/Cclumbus/Cleveland 
- • 2 4 . Grand Rapids 
25. Ann Arbcr/Detrcit 
26. Pittsburgh 
27. Philadelphia 
28. Buffalo/Rochester/Syracuse 
29. Albany/5chenectady/Troy 
30. Bos ton/Providence/Hartford/New Haven/Bridgeport 
31. New York City 
In the first round, Washington, D.C. and Baltimore have 
been inadvertently left out. 
To be decided - Is it more practical to have 20 investigators 
in 20 regions or 10 regions? From A. H. Rathjen's responsi-
bility, it might: be better to consider 10 regions. Practical 
travel itineraries must be considered. 
Next topic brought up by Dr. Elliott was choice cf medical 
monitor. 
1. Several names have been suggested by both A.S.P.R.S. and 
Dow Corning. All names worthy of consideration. 
2. Dr. Robert Goldwyn chosen and highly acceptable. 
Dr. Musgrave elected to inform Dr. Goldwyn of appointment. 
Deadlines and target dates. 
1. Future dates when A.S.P.R.S. members together: 
Association meeting, May 8-11, Chicago. 
June 1-4, Chicago. 
Annual meeting of A.S.P.R.S., October 30-November 4, 
San Francisco. 
*:^S2? 
2. Selection of investigator names by May 8. 
3. A. H. Rathjen suggested training session in October to 
be held at Towsley Center for Postgraduate Medicine in 
Ann Arbor. A. H. Rathjen will investigate possibility. 
4. Dr. Peterson - For training purposes, there should be 
a review of NDA data (similar to Midland svmoosium 
(May 31-June 1,1977) and results of long-term patient 
follow-up from original study. 
Miscellaneous subjects touched on. 
1. A. K. Rathjen/Dow Corning to pay $4,500-5,000 annually 
to Medical Monitor to cover administrative costs of 
program. 
2. When A. H. Rathjen asked to speak at medical meetings, 
there should be a member letter to A.S.R.R.S. newsletter. 
Specifically, this subject was brought up by A. H. Rathjen 
announcement that he was on the New England"Societv!s 
meeting in June. 
3. A.S.R.R.S. ro investigate dollars and investigator posi-
tion relative to potential malpractice claims. Dc\-: Cornin 
to investigate legal question on any product liability 
associated with program. 
4. Other dates to be aware of: 
Bob Goidvyn's symposium, September 15-13. 
ACS meeting in Dallas, October 17-22. 
Symposium in Palm Springs, November. 
Southern Surgical meeting in Dallas, November 7. 
5. Photograph of special map to be sent to Drs. Ray Elliott 
and Ross Musgrave. 
6. All correspondence and phone conversations among Silicone 
Injection Committee and Medical Monitor to be documented 
in writing and circulated. 
7. Request that proposed program be extended one year (from 
two to three years) so patients treated the second year 
will have full opportunity to complete treatment through 
the third year. No new pa'tients will be started in the 
third year of program. 
8, This entire program proposal is subject to approval' by 
the F.D.A. or the new Bureau of Devices if the product 
has been transferred as indicated on December 10, 1976, 
during Dow Coming's meeting at F.D.A. 
*.*'SS2 
The meeting was concluded at approximately 5:20 p.m. A. H. Rath 
to prepare Dow Corning notes and send to Drs. Ross Musgrave and 
Ray Elliott. Both sets of minutes (Dow Comma's and A.S.P.R-S. 
to be combined and final draft circulated. 
c m 
-•.^2--; 
EXHIBIT C 
Mav 13, 1977 
TO: Ross H. Musgrave, M.D., Chairman, ISPAC 
Ray A. Elliott Jr., M.D., Vice Chairman, ISPAC 
FROM: A. H. Rathjen 
Re: ISPAC meeting - Drake Hotel, Chicago, Illinois 
Sunday, May 8, 197 7 - Room M-ll 
Time 12:00pm - 2:00pm (CDST) 
Attended Meeting: 
Rex A. Peterson, M.D. - President, ASPRS 
Peter Randall, M.D. - President Elect, ASPRS 
Bernard E. Simon, M.D. - AAPS 
Garry S. 3rody, M.D. 
Kelman I. Cohen, M.D. 
Robert M. Goldwyn, M.D. - Medical Monitor 
Dallas ?. Whaley, Executive Vice President, ASPRS 
Kerry D. Dingman, Esq., Acting Food & Drug Counsel - Dow C02 
^thur H. Rathjen - Program Coordinator, Dow Corning 
Not Attending: 
Melvin E. Nelson - Dow Corning 
Alvin E. Bey - Dow Corning 
Eugene A. Abbott - Dow Corning 
Steohen W. Guittard - Dow Corning 
This memo has a dual purpose: (1) Respond to Dr. EII 
April 23, IS77 letter request asking for Dov; Coming's written 
acceptance of the ASPRS minutes covering the ISPAC meeting 
in Los Angeles (March 19 77); (2) Acknowledge and comment on 
several of the subjects covered during the May 8, 19 77 meeting 
in Chicago. 
• '^ *** CJ « 
Page two 
A, Minutes Covering Los Angeles_ Meeting 
1. Because Dow Corning has withdrawn active pursuit of the NDA, 
the special, sterile injectable silicone fluid that will be 
used in the Service IND should continue to be identified 
as MDX4-4011 and not identified with a commercial brand 
name. I have one problem with this—the ampules that will 
be used for this Service IND have Dymasyl© as part of their 
label. 
I will solve this, but it is important tha 
not have a commercial overtone, therefore, 
future reference to the injectable fluid s 
2. On page 2, Section 2 ("Length of Program"), item (c), 
NOTE: Number one (1) should be changed to read: 
"Dow Corning has no intention now, or 
in the foreseeable future to actively 
pursue FDA. approval of the NDA on 
MDX4-4011 (Dymasyl©) nor does it have 
any present plans to market this 
product to the medical profession. ,T 
3. On page 2, Section 2 ("Length of Program"), item (c) , 
NOTE: Number two (2) should be deleted in its entirety. 
On page 2, Section 4 (Medical Monitor), item (c) is 
to be deleted. 
5. On page 3, Section 5 (Selection of Treatment Team), item (b) 
is to be deleted. 
6. On page 4, Number 9 (Thoughts on Drug Control), item (a) 
which deals with dosage vial should be clarified. The 
present statement should be changed to read: 
"Ampules to be supplied during Service 
IND will each contain a dosage level 
of l.Scc." 
this program 
ail present and 
ouid be MDX4-4Q11 
••; 9 7 8 : 
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7. On page 4, number 9 (Thoughts on Drug Control), item (b) 
relating to the numbering of each vial. It should read: 
"if feasible, practical and not too 
expensive, a numbering system for 
amoules will be considered." 
Comments on Topics Covered During Meeting 
Support for Medical Monitor 
Pursuant: to the discussion on support of the medical 
monitor's administrative expenses, it is understood that 
the ASPRS Executive Office in Chicago will establish a special 
"Line Item Project Fund" wherein the ASPRS and Dow Corning 
will share these expenses for the duration of the Service 
IND. Dow Coming's payment into the fund will net be made 
until an official "recuest" is received from the ASPRS. 
II. Dow Corning Expenses 
1. It is estimated that Dow Coming's expenses to support 
the Service IND, (not counting personnel salaries, etc.), 
could be as high as 350,000. To offset, in part, these 
expenses where there will be no R.O.I., A. H. Rathjen 
presented a proposal to ISPAC members which suggested 
that Dow Corning will charge a Five Dollar (§5.00) per 
ampule price for the MDX4-4011. 
Although the actual carton quantity and type of shipping 
carton has to be worked out to its final and acceptable 
entity, for the sake of discussion, let's assume that 
the shipping carton contains 10 ampules and the minimum 
quantity shipped to an "injector" is two (2) cartons 
(20 ampules)—20 each - l.Scc ampules. Obviously he 
is responsible to account for every single ampule. During 
treatment(s), his supply drops to 10 ampules, so to order, 
he would use a specially coded order card found in the car 
and send it to A. K. Rathjen's attention, at Dow Corning 
with a check, made payable to Dow Corning, for $5.00 x 
the number of ampules in a carton. If we put 10 ampules 
in a carton, the amount is $50.00; if his ampule requireme 
Pace tour 
were 20 units, the check would be made out for $100.00. 
The actual cost of the ampule (s) ($5.00 per ampule) 
could be passed on to the patient, not a penny more! 
Dow Corning wants to minimize packaging and handling 
ccsts and at the same time maintain an accurate inventory 
record of what is used and "on hand" at each of the surge 
offices. A standardized system for quantities for shipme 
will help accomplish this. 
Dow Corning will coordinate closely with Dr. Goldwyn 
on this matter and get back to ISPAC with a more 
detailed olan. 
2. Rathjen presented a proposed expense schedule for the 
upcoming teaching symposium to be held in Ann Arbor, 
October 7-8, 1977. 
(a) Proposed that designated "injectors" pay their 
own travel and hotel accommodations at Campus Inn. 
(b) Proposed that all ASPRS observers pay their own 
travel and hotel accommodations at Campus Inn. 
(c) Up for further clarification and resolution was the 
proposal that Dow Corning would pay accommodations 
for teaching faculty. Rathjen and Dr. Goldwyn will 
work this through and get back to ISPAC with 
a recommendation. 
(d) Dr. Elliott asked Rathjen to discuss with Dr. Dingman 
the possibility of a buffet following the reception 
tentatively planned for Friday evening, October 7, 
at the home of Dr. Dingman. 
(e) Dow Corning would assist financially with the cost 
for meals while group is in Ann Arbor. 
(f) Dr. Ray Elliott asked Rathjen whether Dow Corning 
would be willing to support hotel accommodations? 
Rathjen indicated that Dov; Coming's financial 
commitment to this program is already very high 
and it is unlikely that we would consider assuming 
this additional expense. 
.'^78^ 
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III Proposed Candidates for Participation in Service IND 
Drs. Musgrave and Elliott have prepared and submitted a 
list of 21 candidates with two more to be identified 
(Hawaii and Phoenix, Arizona). Rathjen has taken the 
list to review and will get back to Dr. Musgrave with 
Dow Coming's recommendations on acceptance. Dr. Musgrave 
will then contact candidates for their curriculum vitae. 
IV. Inquiry to Participate in Program by Dr. Richard Webster-
The American Academy of Facial Plastic and Reconstructive 
Surcerv 
Rathjen reviewed the letter from Dr. Richard Webster 
relating to the current program being developed by Dow 
Corning and the ASPRS. 
After some lengthy discussion on how best to handle this 
matter, it was agreed that Dow Corning would answer 
Dr. Webster's letter explaining the rationale behind the 
structuring of the proposed program. 
V. Scheduled Injection Panel at N.E. Plastic Surgery Meeting— 
June 10th in Burlington, VT. 
Rathjen has suggested to ISPAC that the planned panel on 
silicone injection may not be timely. ISPAC members agree. 
Rathjen committed to call Dr. Joseph Murray to discuss matter, 
and then call Dr. Tom Krizek (program chairman) in an attempt 
to have panel cancelled. 
ISPAC is at a- very critical stage in their program planning 
process and it is agreed, generally, that publicity, 
prior to formal FDA approval, etc. is not warranted. 
The meeting ended at approximately 2:10 pm. 
<^7S~ 
EXHIBIT D 
January 7, 1977 
Ross Kusgrave, M.D, 
3600 Forbes Avenue 
Pittsburgh, PA 15213 
Dear Ross: 
As a follow up to our aost recent phone conversation and my 
previous conference call with Rex and Dallas just before the 
holidays/ enclosed is a list of the major headings encompassing' 
the role of the medical monitor. 
Dnder Item 4/ the actual investigator would initial the comple-
tion of Form 3 65 and both the oedicil monitor and Dow Corning 
would be notified simultaneously. 
Under Item 6f for foutine patient data, completed forms would 
be sent directly to Dow Corning wherein my office would check 
the records for completeness. Copies would be sent to Biometric-
Research Institute for tabulation. One of the most important 
monitor functions would be that of evaluating and analyzing 
trends. This would co», in part, from Dr. Hurley's printout. 
It- is easier to observe an overview than attempting to analyze 
progress froa individual cases. 
Each of tbese sections will be amplified in more detail once 
a medical monitor has been identified« 
Best regards^ 
A. H. Rathjen 
Senior Clinical 
Research Specialist 
Medical Broducts Business 
/dlb 
cc: Rex Peterson, M.D. 
Dallas P. Whaley 
Zeke Dennett 
Enclosure 
W3-1 
M e d i c a l w o n i c o r — N e w Silicone Injection P r o g r a m . 
Medical Monitor: 
1. A medical expert and principle liason between study sponsor 
(Dow Corning) and the doctors officially designated as invest-
igators . 
2. As the medical expert, he would have final word on a patient 
candidate who qualifies to enter the study. 
3. Must be available to answer inquiries from investigators relati 
to problems, technique, duration of treatment, etc. 
4. To be the initial contact relative to complications (365 form) 
5. Submit monthly reports concerning: 
A. New patients entering study 
3. Number of patients currently being treated 
C. Number of patients who have completed treatment 
6. Review all completed patient records prior to submission to 
Dow Corning. 
7. Coordinate and assist in the preparation of the biannual repoi 
to the FDA. 
Attend scheduled meetings of the ASPRS silicone injection 
committee. 
9 . 3e available for one meeting a year with Dow Corning personne 
responsible for the study. 
10. Review any submissions to the FDA relative to clinical safetj 
and efficacy of the MDX-4-4011. 
11. Would be' the faculty Dean for the training program prior to 
commencement of the program. 
EXHIBIT E 
SPECIAL CONSENT FOR SILICONE FLUID- INJECTION 
AND PHOTOGRAPHIC DOCUMENTATION 
(IND 2702) 
I. I hereby authorize Dr. &ob*v*- to. LUQQI~P
 t o 
iniect silicone fluid (MDX4-4011) into QPI i* A I A ^ ^ K 
(name of patient) 
to treat a severe defect of the facial area. This procedure 
"is being conducted under the guidelines set forth as an amendmeni 
to IND 2702 (Notice of Claimed Investigational Exemption for a 
New Drug. The study protocol has been submitted to the FDA, 
pursuant to Section 505 (i) of the Federal Food, Drug and 
Cosmetic Act.) 
II. The procedure listed in Paragraph 1 has been explained 
to me by the above doctor and I completely understand the nature 
and consequences of the procedure. The following points have 
been made specifically clear: 
(a) That tnis procedure to inject a special, 
sterile injectable silicone fluid into the soft tissue 
area of the face has undergone limited testing and 
long term results are still being evaluated. .-The 
end results cannot be determined without long term 
follow-up. 
(b) The fluid will be injected with the full 
understanding that pretreatment baseline laboratory 
tests and photographic documentation will be undertaken 
and that yearly re-evaluations will be required. 
(c) Possible complications include the following: 
Fluid Drift 
Edema 
Erythema 
Pain 
Piomentation -
DEPOSITION 
EXHIBIT 
Evidence or silicone, dnit 
either visible or palpable. 
Condition of swelling. A severe 
edema may involve swelling with 
pitting edema on fingertip pressu: 
Reddening of the skin overlying 
an injection site. 
Based on patient's evaluation of 
current pain level. 
Bronzing or discoloration of the 
overlvina an iniection site? 
•"-' ~**~<+^M 
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(d) That research today indicates that the material 
does not cause malignancy in human subjects. 
(e) There is always a possibility that my body may 
not tolerate the silicone fluid. Should the fluid 
accumulate into small cyst-like nodules, it mav require 
drainage by a needle or surgical removal. 
(f) That the skin and underlying tissue may feel 
more firm than normal tissue. 
(g) Good results are expected but not guaranteed. 
III. I am not known to be allergic to anything except: 
(list) _____ AHA<* 
IV. If treatment requires the administration of a local 01 
general anesthetic, I consent to the administration of anesthesia 
given by or under the direction and supervision of the above 
doctor or such anesthesiologist(s) as he shall select and to 
the use of such anesthetics as he may deem advisable with 
the exception of N*i*s _ . 
V. I agree to cooperate with the above surgeon, relative 
to my treatment and posttreatment care, yearly follow-ups and 
in other relevant matters until completely discharged. 
VI. I am aware that the practice or medicine and surgery 
is not an exact science and I acknowledge that no guarantees 
have been made to me as to the results of this course of 
treatment. 
VII. I consent to be photographed before, during and after 
the treatment. I acknowledge and agree that any photographs 
taken in accordance herewith shall remain in the files of the 
above named surgeon and copies will be supplied to and become 
the property of the study sponsor. The photographs will also 
be included in the reports supplied to the FDA,_ in accordance 
with the regulations. If my photographs are appropriate for 
presentation for scientific or educational purposes or for 
publication in scientific journals or textbooks, my consent 
will be obtained. Considering that my treatment is part of a 
limited, specially regulated program, I waive all rights that 
I may have, now or in the future to any claims for payment 
or royalties in connection with the publication of photographs 
taken in accordance herewith, irrespective whether anv charges 
for treatment expenses are made, 
^ I have read the above consent, received answers to my questio 
and fully understand the same and do authorize the above surgeon 
to perform this procedure on me. 
^ IN WITNESS WHEREOF, I have executed the foregoing this 
/r day of J^KXJCV , 1973". 
(Siqnature) 
WITNESS: 
